TY - JOUR
T1 - Metformin versus myoinositol: which is better in obese PCOS patients? A randomized controlled crossover study
AU - Tagliaferri, Valeria
AU - Romualdi, Daniela
AU - Immediata, Valentina
AU - De Cicco, Simona
AU - Di Florio, Christian
AU - Lanzone, Antonio
AU - Guido, Maurizio
PY - 2017
Y1 - 2017
N2 - CONTEXT:
due to the central role of metabolic abnormalities in the pathophysiology of PCOS, insulin sensitising agents have been proposed as a feasible treatment option.
OBJECTIVE:
to investigate which is the more effective between metformin and myoinositol on hormonal, clinical and metabolic parameters in obese patients with polycystic ovary syndrome (PCOS).
STUDY DESIGN:
crossover randomized-controlled study.
PATIENTS:
Thirty-four PCOS obese women (age: 25.62 ± 4.7 years; BMI: 32.55 ± 5.67 kg/m2 ) were randomized to receive metformin (850 mg twice a day) or myoinositol (1000 mg twice a day) for six months. After a three month washout, the same subjects received the other compound for the following six months.
MEASUREMENTS:
Ultrasonographic pelvic examinations, hirsutism score, anthropometric and menstrual pattern evaluation, hormonal profile assays, oral glucose tolerance test (OGTT) and lipid profile at baseline and after 6 months of treatment were performed.
RESULTS:
Both metformin and myoinositol significantly reduced the insulin response to OGTT and improved insulin sensitivity. Metformin significantly decreased body weight, and improved menstrual pattern and Ferriman-Gallwey score. Metformin treatment was also associated with a significant decrease in LH and estradiol levels, androgens and AMH levels. None of these clinical and hormonal changes were observed during myoinositol administration.
CONCLUSIONS:
Both treatments improved the glyco-insulinaemic features of obese PCOS patients,but only metformin seems to exert a beneficial effect on the endocrine and clinical features of the syndrome. This article is protected by copyright. All rights reserved
AB - CONTEXT:
due to the central role of metabolic abnormalities in the pathophysiology of PCOS, insulin sensitising agents have been proposed as a feasible treatment option.
OBJECTIVE:
to investigate which is the more effective between metformin and myoinositol on hormonal, clinical and metabolic parameters in obese patients with polycystic ovary syndrome (PCOS).
STUDY DESIGN:
crossover randomized-controlled study.
PATIENTS:
Thirty-four PCOS obese women (age: 25.62 ± 4.7 years; BMI: 32.55 ± 5.67 kg/m2 ) were randomized to receive metformin (850 mg twice a day) or myoinositol (1000 mg twice a day) for six months. After a three month washout, the same subjects received the other compound for the following six months.
MEASUREMENTS:
Ultrasonographic pelvic examinations, hirsutism score, anthropometric and menstrual pattern evaluation, hormonal profile assays, oral glucose tolerance test (OGTT) and lipid profile at baseline and after 6 months of treatment were performed.
RESULTS:
Both metformin and myoinositol significantly reduced the insulin response to OGTT and improved insulin sensitivity. Metformin significantly decreased body weight, and improved menstrual pattern and Ferriman-Gallwey score. Metformin treatment was also associated with a significant decrease in LH and estradiol levels, androgens and AMH levels. None of these clinical and hormonal changes were observed during myoinositol administration.
CONCLUSIONS:
Both treatments improved the glyco-insulinaemic features of obese PCOS patients,but only metformin seems to exert a beneficial effect on the endocrine and clinical features of the syndrome. This article is protected by copyright. All rights reserved
KW - insulin
KW - insulin
UR - http://hdl.handle.net/10807/94051
M3 - Article
SN - 1365-2265
SP - N/A-N/A
JO - Clinical Endocrinology
JF - Clinical Endocrinology
ER -